{"nctId":"NCT01891864","briefTitle":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","startDateStruct":{"date":"2013-06"},"conditions":["Chronic Stable Plaque Psoriasis"],"count":531,"armGroups":[{"label":"GP2015 Etanercept","type":"EXPERIMENTAL","interventionNames":["Drug: GP2015 Etanercept"]},{"label":"Enbrel ® Etanercept","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enbrel"]}],"interventions":[{"name":"GP2015 Etanercept","otherNames":["GP2015","Etanercept"]},{"name":"Enbrel","otherNames":["Etanercept"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women at least 18 years of age at time of screening\n* Chronic plaque-type psoriasis diagnosed for at least 6 months before baseline\n* Moderate to severe psoriasis as defined at baseline by:\n\n  * PASI score of 10 or greater and,\n  * Investigator´s Global Assessment score of 3 or greater (based on a scale of 0 - 4) and,\n  * Body Surface Area affected by plaque-type psoriasis of 10% or greater\n* Chronic plaque-type psoriasis patients who have previously received phototherapy or systemic psoriasis therapy at least once or who are candidates for such therapies in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Forms of psoriasis other than chronic plaque-type\n* Drug-induced psoriasis\n* Ongoing use of prohibited treatments\n* Previous exposure to etanercept\n* Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of treatment with etanercept\n\nOther In-/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PASI 75 Response Rate at Week 12 - GP2015 Etanercept vs. Enbrel ® Etanercept","description":"The 95% CI for the Psoriasis Area and Severity Index (PASI) 75 response rate differences at Week12 between GP2015 Etanercept and Enbrel ® Etanercept. PASI 75 response: patients who achieved ≥ 75% improvement (reduction) in PASI score compared to baseline were defined as PASI 75 responders. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretic maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"75.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in PASI Score up to Week 12","description":"The key secondary efficacy endpoint was the % change from baseline in PASI score up to Week 12. PASI scores can range from 0, corresponding to no signs of psoriasis up to theoretic maximum of 72.0, which means a higher PASI score reflects a higher psoriasis activity. Two approaches (longitudinal approach applying a Mixed Model Repeated Measures and Averaged Treatment Effect approach applying an ANCOVA model) were employed in order to calculate 2-sided 95% confidence intervals (CI) for the difference between the treatment groups.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.11","spread":"1.0578"},{"groupId":"OG001","value":"-55.48","spread":"1.0511"}]}]}]},{"type":"SECONDARY","title":"PASI 50, 75 and 90 Response Rates","description":"Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 75, and PASI 90 responses at Week 12. PASI 50 response: patients who achieved ≥ 50% improvement (reduction) in PASI score compared to baseline were defined as PASI 50 responders .PASI 90 response: patients who achieved ≥ 90% improvement (reduction) in PASI score compared to baseline were defined as PASI 90 responders .","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"97.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.4","spread":null},{"groupId":"OG001","value":"75.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","spread":null},{"groupId":"OG001","value":"34.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Injection Site Reactions","description":"Percentage of patients with injection site reactions up to Week 52","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"9.0","spread":null},{"groupId":"OG003","value":"15.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity: Measurement of Rate of ADA Formations Against GP2015 Etanercept and Enbrel ® Etanercept","description":"Immunogenicity was analyzed by the percentage of patients with positive anti-drug antibodies (ADA) to either GP2015 Etanercept or Enbrel ® up to Week 52.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":164},"commonTop":["Nasopharyngitis","Pharyngitis","Viral upper respiratory tract infection","Arthralgia","Headache"]}}}